篇名 | 2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in Taiwan |
---|---|
卷期 | 34:3 |
作者 | Yi-Heng Li 、 Chih-Yuan Fang 、 I-Chang Hsieh 、 Wei-Chun Huang 、 Tsung-Hsien Lin 、 Shih-Hsien Sung 、 Chiung-Zuan Chiu 、 Chiung-Jen Wu 、 Kou-Gi Shyu 、 Po-Yuan Chang 、 Ching-Chang Fang 、 Tse-Min Lu 、 Ching-Pei Chen 、 Wei-Chen Tai 、 Chau-Chyun Sheu 、 Kai-Che Wei 、 Yi-Hsiu Huang 、 Hsing-Mei Wu 、 Juey-Jen Hwang |
頁次 | 201-210 |
關鍵字 | Acute coronary syndrome 、 Antiplatelet therapy 、 Expert consensus 、 Guidance 、 MEDLINE 、 SCI 、 Scopus |
出刊日期 | 201805 |
DOI | 10.6515/ACS.201805_34(3).20180302A |
Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of newand more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.